Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcast
August: Episode 2 Watch time: 25 min
Psoriasis post-COVID-19: an era of virtual clinics?
Episode two focuses on psoriasis management and treatment considerations in light of COVID-19, sharing experiences of overcoming challenges in individual clinics, and top tips for optimising clinic set-up and psoriasis management now and into the future.2-4
Podcast Series Host
Dr Laura Savage
University of Leeds and Leeds
Teaching Hospitals NHS Trust
Podcast Guest Speakers
Dr Tony Bewley
Barts Health NHS Trust,
The Royal London Hospital and Whipps Cross University Hospitals NHS Trust, London
Lucy Moorhead
St John’s Institute of Dermatology,
Guys Hospital, London
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
- NICE rapid guideline ng169: https://www.nice.org.uk/guidance/ng169 (Accessed August 2020).
- PsoProtect. https://psoprotect.org (Accessed August 2020).
- BAD risk stratification grid: https://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=6674 (Accessed August 2020).
UK-RISN-210513 Date of Preparation: October 2021
